Abelacimab
As of the edition of 20 October 2026, Abelacimab is an antibody: in active development; acts on F11.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Antibody
- Registered trials
- 5, 2 stopped early
- Disease areas
- Heart and blood vessels; Lungs and airways; Cancer; Digestive system; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| F11 | Coagulation factor XI | P03951 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 1 | 0 | 1 | 0 |
| Phase 3 | 4 | 0 | 2 | 2 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Anthos Therapeutics | Lead sponsor of trials | 2021 to now |
| Novartis | Lead sponsor of trials | 2027 to now |